While drug development requirements do not differ between large pharma and small biotech with respect to health authority regulations, how these activities are managed and conducted varies widely.
Carol Ohmstede is a graduate of the University of South Florida with a degree in Biochemistry. She is currently Associate Director of Project Management at Gilead Sciences in Durham. Prior to joining Gilead, she held various positions in project management and alliances at Trimeris, Inc. and at Glaxo Wellcome.
Carol will describe her experiences in managing drug development projects and project teams from her perspectives of large pharma, mid pharma and start-up biotech.
